Approval · Notice of Compliance 517 · 2003
INTEGRILIN: Notice of Compliance 517
Issued November 19, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 517
- Date
- November 19, 2003
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication for treatment of patients undergoing percutaneous coronary intervention
- Therapeutic class
- Platelet aggregation inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| INTEGRILIN | Not yet assigned | — |
Medicinal ingredients
- EPTIFIBATIDE 2 MG per ML
- EPTIFIBATIDE 0.75 MG per ML